Extensive Stage Small Cell Lung Cancer

Oncology
7
Pipeline Programs
7
Companies
21
Clinical Trials
10 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

Amgen
IMDELLTRAApproved
tarlatamab-dlle
Amgen
injection2024

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
1
IMDELLTRA(Tarlatamab)Phase 1Monoclonal Antibody5 trials
Active Trials
NCT06064500Approved For Marketing
NCT07203053Not Yet Recruiting48Est. Oct 2029
NCT07423585Recruiting39Est. Dec 2027
+2 more trials
Novartis
NovartisBASEL, Switzerland
1 program
1
[177Lu]Lu-DOTA-TATEPhase 1/21 trial
Active Trials
NCT05142696Active Not Recruiting24Est. Mar 2029
CP
Chugai PharmaJapan - Tokyo
1 program
1
ALPS12Phase 11 trial
Active Trials
NCT07107490Recruiting122Est. Sep 2028
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
TarlatamabPhase 1Monoclonal Antibody
Asher Biotherapeutics
1 program
1
TarlatamabPhase 1Monoclonal Antibody
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposidePhase 11 trial
Active Trials
NCT04346914Unknown20Est. Oct 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
AmgenTarlatamab
Novartis[177Lu]Lu-DOTA-TATE
Chugai PharmaALPS12
AmgenTarlatamab

Showing 15 of 20 trials with date data

Clinical Trials (21)

Total enrollment: 3,142 patients across 21 trials

NCT06211036AmgenTarlatamab

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Start: Jun 2024Est. completion: Sep 2028563 patients
Phase 3Active Not Recruiting
NCT05740566AmgenTarlatamab

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Start: May 2023Est. completion: Mar 2028509 patients
Phase 3Active Not Recruiting
NCT07203053AmgenTarlatamab

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

Start: May 2026Est. completion: Oct 202948 patients
Phase 2Not Yet Recruiting
NCT07423585AmgenTarlatamab

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Start: Apr 2026Est. completion: Dec 202739 patients
Phase 2Recruiting
NCT07061080AmgenTarlatamab

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

Start: Dec 2025Est. completion: Dec 202887 patients
Phase 2Recruiting
NCT07111507AmgenTarlatamab

A Study of Tarlatamab for People With Prostate Cancer

Start: Jul 2025Est. completion: Aug 202732 patients
Phase 2Recruiting
NCT06816394AmgenTarlatamab

Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

Start: May 2025Est. completion: Apr 202932 patients
Phase 2Not Yet Recruiting
NCT06788938AmgenTarlatamab

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Start: Mar 2025Est. completion: Apr 202929 patients
Phase 2Recruiting
NCT06745323AmgenTarlatamab

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Start: Feb 2025Est. completion: Feb 2029252 patients
Phase 2Active Not Recruiting
NCT06502977AmgenTarlatamab

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Start: Aug 2024Est. completion: Jan 202732 patients
Phase 2Active Not Recruiting
NCT07243470AmgenTarlatamab

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Start: Nov 2025Est. completion: Oct 203070 patients
Phase 1/2Recruiting
NCT06814496AmgenTarlatamab

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Start: Sep 2025Est. completion: May 203030 patients
Phase 1/2Recruiting
NCT05142696Novartis[177Lu]Lu-DOTA-TATE

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Start: Jul 2022Est. completion: Mar 202924 patients
Phase 1/2Active Not Recruiting
NCT07107490Chugai PharmaALPS12

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Start: Oct 2025Est. completion: Sep 2028122 patients
Phase 1Recruiting
NCT07037758AmgenTarlatamab

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Start: Sep 2025Est. completion: Jan 2031380 patients
Phase 1Recruiting
NCT06898957AmgenTarlatamab

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Start: May 2025Est. completion: Apr 2031200 patients
Phase 1Recruiting
NCT06598306AmgenTarlatamab

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Start: Oct 2024Est. completion: Mar 2030220 patients
Phase 1Recruiting
NCT05361395AmgenTarlatamab

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Start: Aug 2022Est. completion: Aug 2028184 patients
Phase 1Active Not Recruiting
NCT04346914Lee's Pharmaceuticalrecombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide

Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Start: Mar 2020Est. completion: Oct 202220 patients
Phase 1Unknown
NCT03319940AmgenTarlatamab

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Start: Dec 2017Est. completion: Dec 2027269 patients
Phase 1Active Not Recruiting
NCT06064500AmgenTarlatamab

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

N/AApproved For Marketing

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 actively recruiting trials targeting 3,142 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)